Anavex Life Sciences Unveils Promising Results in Parkinson’s Disease Study
OnAnavex Life Sciences, a clinical-stage biopharmaceutical company, announced significant advancements in its treatment for Parkinson’s disease dementia, ANAVEX®2-73 (blarcamesine). The recent 48-week Phase 2.
Read More